skip to content
Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness Preview this item
ClosePreview this item
Checking...

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness

Author: Canadian Agency for Drugs and Technologies in Health.
Publisher: [Ottawa, Ont.] : Canadian Agency for Drugs and Technologies in Health, 2012.
Series: Rapid response report.
Edition/Format:   eBook : Document : English
Summary:
Chronic obstructive pulmonary disease (COPD) is a major respiratory illness affecting over 700, 000 Canadians and is preventable and treatable, but not curable. It is the fourth leading cause of death in Canada, with mortality rates increasing over the past fifteen years, especially in women. According to the Canadian Institute for Health Information, COPD accounts for the highest rate of hospital admission and  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health.
OCLC Number: 818083658
Notes: "29 Aug 2012."
Description: 1 online resource (12 pages) : tables, digital file.
Contents: Pages:1 to 8; Pages:9 to 12.
Series Title: Rapid response report.
Responsibility: [prepared by Canadian Agency for Drugs and Technologies in Health].
More information:

Abstract:

Chronic obstructive pulmonary disease (COPD) is a major respiratory illness affecting over 700, 000 Canadians and is preventable and treatable, but not curable. It is the fourth leading cause of death in Canada, with mortality rates increasing over the past fifteen years, especially in women. According to the Canadian Institute for Health Information, COPD accounts for the highest rate of hospital admission and readmission among major chronic diseases in Canada. Exacerbations are the principal cause of hospitalizations. Management should be patient focused, consisting of a combination of risk factor reduction, pharmacotherapy, education, pulmonary rehabilitation, and exercise programs to improve symptoms and activity levels, reduce exacerbations, and improve or maintain overall quality of life. Smoking cessation is the most effective intervention that reduces the risk of developing COPD and the only intervention that has been shown to slow the rate of lung function decline. Pharmacotherapy is introduced in a step wise approach. Bronchodilators are the cornerstone of COPD therapy and include inhaled short and long acting beta-2 agonists and short and long acting anticholinergics. They act by decreasing airway smooth muscle tone, which increases expiratory flow rates and reduces hyperinflation with a subsequent reduction in dyspnea, improved exercise tolerance, and health status. The two anticholinergics available in Canada are ipratropium bromide, a short acting agent available as nebules and metered dose inhaler dosed up to four times a day and tiotropium bromide, a long acting agent available as capsules that are inhaled via a Handihaler device with once daily dosing. Ipratropium and tiotropium are recommended separately for the treatment of COPD. A Rapid Response regarding this topic was produced by CADTH in 2009, with the conclusion that, "spirometery measures typically did not differ between treatments over this time period. Further, symptoms of COPD did not differ between tiotropium and ipratropium and other important outcomes such as functional capacity and quality of life was not assessed". There is still continuing pressure for policy makers to provide tiotropium as a general benefit. A review of the literature for new evidence regarding the clinical effectiveness of ipratropium compared to tiotropium may help to clarify if a change in policy is warranted.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/818083658> # Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness
    a schema:CreativeWork, schema:MediaObject, schema:Book ;
   library:oclcnum "818083658" ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/1181780635#Place/ottawa_ont> ; # Ottawa, Ont.
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/1181780635#Topic/evaluation_studies> ; # Evaluation Studies
   schema:about <http://experiment.worldcat.org/entity/work/data/1181780635#Topic/pulmonary_disease_chronic_obstructive_drug_therapy> ; # Pulmonary Disease, Chronic Obstructive--drug therapy
   schema:about <http://experiment.worldcat.org/entity/work/data/1181780635#Topic/scopolamine_derivatives_therapeutic_use> ; # Scopolamine Derivatives--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/1181780635#Topic/bronchodilator_agents_therapeutic_use> ; # Bronchodilator Agents--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/1181780635#Topic/ipratropium_therapeutic_use> ; # Ipratropium--therapeutic use
   schema:about <http://id.worldcat.org/fast/1003802> ; # Lungs--Diseases, Obstructive--Chemotherapy
   schema:about <http://dewey.info/class/616.24/e23/> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/1181780635#Topic/lungs_diseases_obstructive_chemotherapy> ; # Lungs--Diseases, Obstructive--Chemotherapy
   schema:about <http://id.worldcat.org/fast/839417> ; # Bronchodilator agents
   schema:bookFormat schema:EBook ;
   schema:contributor <http://viaf.org/viaf/145374402> ; # Canadian Agency for Drugs and Technologies in Health.
   schema:datePublished "2012" ;
   schema:description "Chronic obstructive pulmonary disease (COPD) is a major respiratory illness affecting over 700, 000 Canadians and is preventable and treatable, but not curable. It is the fourth leading cause of death in Canada, with mortality rates increasing over the past fifteen years, especially in women. According to the Canadian Institute for Health Information, COPD accounts for the highest rate of hospital admission and readmission among major chronic diseases in Canada. Exacerbations are the principal cause of hospitalizations. Management should be patient focused, consisting of a combination of risk factor reduction, pharmacotherapy, education, pulmonary rehabilitation, and exercise programs to improve symptoms and activity levels, reduce exacerbations, and improve or maintain overall quality of life. Smoking cessation is the most effective intervention that reduces the risk of developing COPD and the only intervention that has been shown to slow the rate of lung function decline. Pharmacotherapy is introduced in a step wise approach. Bronchodilators are the cornerstone of COPD therapy and include inhaled short and long acting beta-2 agonists and short and long acting anticholinergics. They act by decreasing airway smooth muscle tone, which increases expiratory flow rates and reduces hyperinflation with a subsequent reduction in dyspnea, improved exercise tolerance, and health status. The two anticholinergics available in Canada are ipratropium bromide, a short acting agent available as nebules and metered dose inhaler dosed up to four times a day and tiotropium bromide, a long acting agent available as capsules that are inhaled via a Handihaler device with once daily dosing. Ipratropium and tiotropium are recommended separately for the treatment of COPD. A Rapid Response regarding this topic was produced by CADTH in 2009, with the conclusion that, "spirometery measures typically did not differ between treatments over this time period. Further, symptoms of COPD did not differ between tiotropium and ipratropium and other important outcomes such as functional capacity and quality of life was not assessed". There is still continuing pressure for policy makers to provide tiotropium as a general benefit. A review of the literature for new evidence regarding the clinical effectiveness of ipratropium compared to tiotropium may help to clarify if a change in policy is warranted."@en ;
   schema:description "Pages:1 to 8; Pages:9 to 12."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/1181780635> ;
   schema:genre "Electronic books"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1181780635#Series/rapid_response_report_summary_with_critical_appraisal> ; # Rapid response report, summary with critical appraisal
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1181780635#Series/rapid_response_report> ; # Rapid response report.
   schema:name "Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness"@en ;
   schema:productID "818083658" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/818083658#PublicationEvent/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2012> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/1181780635#Agent/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health
   schema:url <http://site.ebrary.com/id/10610543> ;
   schema:url <http://public.eblib.com/choice/publicfullrecord.aspx?p=3282304> ;
   schema:url <http://www.deslibris.ca/ID/234402> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/818083658> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/1181780635#Agent/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health
    a bgn:Agent ;
   schema:name "Canadian Agency for Drugs and Technologies in Health" ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Series/rapid_response_report> # Rapid response report.
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/818083658> ; # Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness
   schema:name "Rapid response report." ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Series/rapid_response_report_summary_with_critical_appraisal> # Rapid response report, summary with critical appraisal
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/818083658> ; # Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness
   schema:name "Rapid response report, summary with critical appraisal" ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Topic/bronchodilator_agents_therapeutic_use> # Bronchodilator Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Bronchodilator Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Topic/ipratropium_therapeutic_use> # Ipratropium--therapeutic use
    a schema:Intangible ;
   schema:name "Ipratropium--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Topic/lungs_diseases_obstructive_chemotherapy> # Lungs--Diseases, Obstructive--Chemotherapy
    a schema:Intangible ;
   schema:hasPart <http://id.loc.gov/authorities/subjects/sh85078908> ;
   schema:name "Lungs--Diseases, Obstructive--Chemotherapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Topic/pulmonary_disease_chronic_obstructive_drug_therapy> # Pulmonary Disease, Chronic Obstructive--drug therapy
    a schema:Intangible ;
   schema:name "Pulmonary Disease, Chronic Obstructive--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1181780635#Topic/scopolamine_derivatives_therapeutic_use> # Scopolamine Derivatives--therapeutic use
    a schema:Intangible ;
   schema:name "Scopolamine Derivatives--therapeutic use"@en ;
    .

<http://id.worldcat.org/fast/1003802> # Lungs--Diseases, Obstructive--Chemotherapy
    a schema:Intangible ;
   schema:name "Lungs--Diseases, Obstructive--Chemotherapy"@en ;
    .

<http://id.worldcat.org/fast/839417> # Bronchodilator agents
    a schema:Intangible ;
   schema:name "Bronchodilator agents"@en ;
    .

<http://viaf.org/viaf/145374402> # Canadian Agency for Drugs and Technologies in Health.
    a schema:Organization ;
   schema:name "Canadian Agency for Drugs and Technologies in Health." ;
    .

<http://www.worldcat.org/title/-/oclc/818083658>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/818083658> ; # Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease : a review of the clinical effectiveness
   schema:dateModified "2017-12-25" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.